Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Vpliv povprečne doze na srce na umrljivost po visokodoznem obsevanju raka pljuč
Authors:ID Šketa, Katja (Author)
ID Tomazin, Anja (Author)
ID Ratoša, Ivica (Author)
ID Elbl, Urška (Author)
ID Sojar, Magdalena (Author)
ID Brojan, Denis (Author)
ID Antolič, Bor (Author)
ID But-Hadžić, Jasna (Author)
Files:.pdf PDF - Presentation file, download (180,17 KB)
MD5: E9AE3897E46AB38C52065A8B577026E1
 
Language:Slovenian
Typology:1.01 - Original Scientific Article
Organization:Logo OI - Institute of Oncology
Abstract:Izhodišča: Srčno-žilni zapleti predstavljajo pomemben pozni neželeni učinek obsevanja prsnega koša pri bolnikih z rakom pljuč. Povprečna doza na srce (mean heart dose – MHD) je pogosto uporabljen dozimetrični parameter pri načrtovanju obsevanja, vendar optimalna pragovna vrednost, povezana s preživetjem bolnikov, še ni jasno opredeljena. Namen raziskave je bil oceniti vpliv MHD na celokupno preživetje bolnikov po visokodoznem obsevanju raka pljuč. Metode: Retrospektivno smo analizirali bolnike z rakom pljuč, zdravljene z obsevanjem na Onkološkem inštitutu Ljubljana v obdobju 2018–2022. Analizirali smo klinične značilnosti bolnikov, podatke o zdravljenju ter dozimetrične parametre iz obsevalnih načrtov. Povprečno dozo na srce smo analizirali po intervalih 5 Gy. Celokupno preživetje smo ocenili s Kaplan- -Meierjevo metodo, vpliv posameznih dejavnikov pa s Coxovo regresijsko analizo. Rezultati: V analizo je bilo vključenih 460 bolnikov. Srednja starost je bila 66 let, večina bolnikov pa je imela lokoregionalno napredovalo bolezen (stadij III). V srednjem času sledenja 28,5 meseca je bilo srednje celokupno preživetje 28,3 meseca (95-% IZ 25,2–31,6). Povprečna doza na srce je bila 9,09 Gy (razpon 0,05–34,79 Gy). Pri primerjavi skupin glede na prag MHD 20 Gy so bolniki z MHD < 20 Gy dosegli daljše preživetje (31,1 meseca; 95-% IZ 26,7–35,4) v primerjavi z bolniki z MHD ≥ 20 Gy (23,5 meseca; 95-% IZ 16,2–30,8; p = 0,020). V multivariatni analizi je bila MHD ≥ 20 Gy neodvisno povezana s slabšim preživetjem (HR 1,54; 95-% IZ 1,12–2,11; p = 0,008). Pomembna napovedna dejavnika sta bila tudi starost ≥ 65 let (HR 1,66; p < 0,001) in slabše stanje zmogljivosti (HR 2,02; p < 0,001). Zaključek: Povprečna doza na srce predstavlja pomemben prognostični dejavnik pri obsevanju raka pljuč. Naši rezultati kažejo, da je MHD < 20 Gy povezana z boljšim celokupnim preživetjem, kar podpira uporabo te omejitve pri načrtovanju visokodoznega obsevanja raka pljuč. Nadaljnje analize doz na posamezne srčne podstrukture bodo omogočile natančnejšo opredelitev kritičnih srčnih struktur in izboljšale individualizacijo obsevalnega načrtovanja.
Keywords:obsevanje pljuč, rak pljuč, srčno-žilni zapleti
Publication status:Published
Publication version:Version of Record
Publication date:01.06.2026
Publisher:Onkološki inštitut
Year of publishing:2026
Number of pages:str. 8-12
Numbering:Letn. 30, št. 1
Source:Ljubljana
PID:20.500.12556/DiRROS-31389 New window
UDC:616-006
ISSN on article:1408-1741
COBISS.SI-ID:286170883 New window
Copyright:by Authors
Publication date in DiRROS:31.07.2026
Views:62
Downloads:22
Metadata:XML DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Onkologija
Shortened title:Onkologija
Publisher:Onkološki inštitut
ISSN:1408-1741
COBISS.SI-ID:65324032 New window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:English
Title:Impact of mean heart dose on mortality after high-dose radiotherapy for lung cancer
Abstract:Background: Cardiovascular complications represent an important late adverse effect of thoracic radiotherapy in patients with lung cancer. Mean heart dose (MHD) is a commonly used dosimetric parameter in radiotherapy planning; however, the optimal threshold associated with patient survival has not yet been clearly defined. The aim of this study was to evaluate the impact of MHD on overall survival following high-dose radiotherapy for lung cancer. Methods: We retrospectively analysed patients with lung cancer treated with thoracic radiotherapy at the Institute of Oncology Ljubljana between 2018 and 2022. Clinical characteristics, treatment data, and dosimetric parameters from radiotherapy plans were analysed. Mean heart dose was evaluated in 5-Gy increments. Overall survival was estimated using the Kaplan-Meier method, and the impact of individual variables was assessed using Cox regression analysis. Results: A total of 460 patients were included in the analysis. The mean age was 66 years, and the majority of patients had locally advanced disease (stage III). With a median follow-up of 28.5 months, the median overall survival was 28.3 months (95% CI 25.2- 31.6). The mean heart dose was 9.09 Gy (range 0.05-34.79 Gy). When comparing groups according to the MHD threshold of 20 Gy, patients with MHD < 20 Gy had longer survival (31.1 months; 95% CI 26.7-35.4) compared with patients with MHD ≥ 20 Gy (23.5 months; 95% CI 16.2-30.8; p = 0.020). In multivariable analysis, MHD ≥ 20 Gy was independently associated with worse overall survival (HR 1.54; 95% CI 1.12-2.11; p = 0.008). Age ≥ 65 years (HR 1.66; p < 0.001) and poorer performance status (HR 2.02; p < 0.001) were also significant prognostic factors. Conclusion: Mean heart dose represents an important prognostic factor in lung cancer radiotherapy. Our results show that MHD < 20 Gy is associated with improved overall survival, supporting the use of this constraint in high-dose radiotherapy planning for lung cancer. Further analyses of radiation dose to individual cardiac substructures may help identify critical cardiac regions and improve individualized radiotherapy planning.
Keywords:thoracic radiotherapy, lung cancer, cardiovascular complications


Back